Clinical trial

Improving Detection and Evidence-based Care of NAFLD in Latinx and Black Patients With Type 2 Diabetes (NAFLD-DM): A Pilot Study

Name
Pro00113239
Description
The primary objective of this pilot study is to assess the feasibility and acceptability of an intervention for improved detection and evidence-based care of NAFLD in Latinx and Black patients with type 2 diabetes (T2D) in Duke University Healthcare system (DUHS). We will enroll 10-15 Latinx and 10-15 Black patients with T2D and NAFLD, based on having mildly elevated liver enzymes (ALT \>/= 40 IU/mL in males, ALT \>/= 31 IU/mL in females) and exclusion of other liver diseases (e.g., viral hepatitis, alcohol abuse). Intervention content will include: 1) NAFLD education; 2)diet/lifestyle support; 3) T2D medication management; and 4) clinically-indicated liver testing and care. Intervention feasibility will be evaluated by examining recruitment rates, retention rates, and study visit completion rates. Acceptability will be assessed by survey and through qualitative interviews. The project objectives and intervention are minimal risk. The expected risks will not exceed those of usual care.
Trial arms
Trial start
2023-09-18
Estimated PCD
2024-01-29
Trial end
2024-01-29
Status
Completed
Treatment
NAFLD Education
NAFLD Education
Arms:
Evidence-based care of NAFLD in T2D
diet/lifestyle support
diet/lifestyle support
Arms:
Evidence-based care of NAFLD in T2D
T2D medication management
T2D medication management
Arms:
Evidence-based care of NAFLD in T2D
clinically-indicated liver testing and care
clinically-indicated liver testing and care
Arms:
Evidence-based care of NAFLD in T2D
Size
10
Primary endpoint
Feasibility as measured by recruitment rate
3months
Feasibility as measured by retention rate
3months
Feasibility as measured by visit completion rate
3months
Feasibility of system-level NAFLD detection approach
Baseline
Acceptability of intervention by participants
3months
Eligibility criteria
Inclusion Criteria: * People who identify as either: Latino/Latina/Hispanic ethnicity and/or Black or African American race * People with type 2 diabetes (T2D), as defined by ICD-10 codes E11.xx. * Patients with elevated serum alanine aminotransferase (ALT) within Duke University Healthcare System (DUHS). Elevated ALT will be defined as having at least two ALT ≥40 IU/mL in males or ≥31 IU/mL in females in the preceding 12 months Exclusion Criteria: * People with hepatitis B or C infection * People with known alcohol overuse * People with current use of chemotherapy or other drugs known to affect liver function * People who have not been seen by a DUHS Primary Care Physician (PCP) or Endocrinologist in the preceding year.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 10, 'type': 'ACTUAL'}}
Updated at
2024-03-25

1 organization

1 product

2 indications

Organization
Duke University
Indication
NAFLD